Vaxcyte reported that its 31-valent pneumococcal conjugate vaccine (VAX-31) met key endpoints in a Phase 3 trial in adults, setting up competitive positioning against established vaccines. The news triggered a sharp stock move, reflecting investor focus on serotype breadth and immunogenicity outcomes. In the trial, just over 3,500 adults age 50 and older were randomized to VAX-31, Prevnar, or Capvaxive, with investigators measuring antibody responses across targeted serotypes. The company’s program is designed to extend pneumococcal coverage while maintaining comparable immune responses. The results place Vaxcyte in a stronger position for later regulatory and commercialization discussions, as the next wave of pneumococcal products leans on both serotype expansion and immunogenicity consistency.